Safety of immunomodulatory systemic therapies used in the management of immune-related cutaneous adverse events Review
| Authors: | Gu, S. L.; Nath, S.; Markova, A. |
| Review Title: | Safety of immunomodulatory systemic therapies used in the management of immune-related cutaneous adverse events |
| Abstract: | Immune-related cutaneous adverse events (ircAEs) commonly occur in patients on treatment with immune checkpoint inhibitors and can significantly reduce patient quality of life. These are often treated with immunomodulatory agents, including glucocorticoids, immunosuppressants, and biologics. While often effective at managing symptoms, these therapies can cause several adverse events which may limit their use. In addition, immunomodulatory agents should be used with particular caution in patients receiving immunotherapy, as the efficacy of the oncologic regimen may potentially be undermined. In this review, we summarize the safety of systemic therapies that are used in the management of ircAEs, with a particular focus on the resultant risk of secondary tumor progression in patients with active cancer. © 2023 by the authors. |
| Keywords: | prednisone; fatigue; review; diarrhea; hypertension; systemic therapy; methotrexate; rituximab; edema; infection; liver toxicity; breast cancer; anemia; leukopenia; nausea; stomatitis; thrombocytopenia; vomiting; myalgia; dexamethasone; abdominal pain; arthralgia; dizziness; dyspnea; fever; hyperglycemia; pruritus; rash; insomnia; prednisolone; immunotherapy; glucocorticoid; cataract; hydroxychloroquine; methylprednisolone; safety; azathioprine; pancytopenia; headache; osteoporosis; glaucoma; alopecia; hearing impairment; cyclosporine; myopathy; hypertrichosis; mouth squamous cell carcinoma; conjunctivitis; hypertransaminasemia; peptic ulcer; inflammatory bowel disease; tocilizumab; mycophenolate mofetil; infusion related reaction; human; mild renal impairment; omalizumab; biologics; ustekinumab; dupilumab; acitretin; immune-related cutaneous adverse events; apremilast; benralizumab; gingiva hyperplasia |
| Journal Title: | Pharmaceuticals |
| Volume: | 16 |
| Issue: | 11 |
| ISSN: | 1424-8247 |
| Publisher: | MDPI |
| Date Published: | 2023-11-01 |
| Start Page: | 1610 |
| Language: | English |
| DOI: | 10.3390/ph16111610 |
| PROVIDER: | scopus |
| PMCID: | PMC10674388 |
| PUBMED: | 38004475 |
| DOI/URL: | |
| Notes: | Review -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Alina Markova -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work